OcluMed™
Eye Drops

Senile cataracts are generally thought to be the result of free radical damage to DNA areas that encode for lens proteins. The result is that the body produces faulty proteins that are not completely transparent. Eventually this accumulation of errors develops into what is medically recognized as a cataract. The eye protects its DNA from damage with numerous antioxidant systems. In the development of a senile cataract, it is reasonable to assume that more than one of these antioxidant systems have been compromised or damaged.

This results in an accrual of damage at a faster rate than repair can take place in the eye. Previous attempts to treat senile cataracts have focused on single components such as L-Carnosine or N-Acetyl-L-Carnosine as antioxidants. These types of eye drop treatments have met with only very limited success because no single antioxidant developed previously has been powerful enough to compensate for all the compromised systems in the eye.

As a result of this, we reasoned that a systems approach to supplementing the major antioxidant systems in the eye might be more efficacious. As a result, we focused our research on a multifaceted approach that incorporates a formula comprising numerous antioxidants; each designed to support a failing antioxidant system in the eye. For example:

• L-Carnosine is used in the formula to provide immediate neutralization of existing free radicals.
• N-Acetyl-L-Carnosine provides a longer-term of protection due to its longer residence and activity time in the cells.
• L-Glutathione was added, as it may be the single most important antioxidant in the lens.
• Cysteine Ascorbate was developed to provide a water stable source of both Vitamin C (an important antioxidant in the eye) and L-Cysteine.
• L-Cysteine is used to regenerate or reduce oxidized L-Glutathione in the eye.
• Other nutrients were added to support the repair of the damaged lens tissues, etc.

The result is a complex system which is far more effective than a single ingredient approach, since it is able to slow or stop damage on a much wider scale than a single component approach. This systems method of improving vision and treating senile cataracts is claimed in our pending patents and its efficacy and superiority is supported by our treatment results, which distinguishes our eye drop from other previous attempts to reduce oxidative damage in the eye that allows the eye to repair the cataract.